{"filings":[{"id":555321,"accession_number":"0001193125-26-232707","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2026-05-20T20:30:32+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lilly completes $9B multi-tranche debt offering tied to Centessa acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Completed $9.0B aggregate principal debt offering across eight tranches of floating and fixed-rate notes due 2026-2066.","Net proceeds of ~$8.94B after underwriting discounts; proceeds intended for general corporate purposes including the Centessa Acquisition.","Interest rates: floating at SOFR+0.350% (2028) or +0.460% (2029); fixed rates from 4.150% to 5.700%.","Certain notes (2029 floating, 2029/2031/2033/2036 fixed) subject to mandatory redemption at 101% if Centessa Acquisition not closed by March 31, 2027.","Notes issued under existing indenture; underwriters include Morgan Stanley, Citigroup, Deutsche Bank, Goldman Sachs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98253,"accession_number":"0000059478-26-000048","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lilly shareholders re-elect directors, reject board declassification and supermajority proposals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four directors (Bertozzi, Kaelin, Moeller, Ricks) elected; say-on-pay approved with 95.7% of votes cast.","Board declassification proposal failed: 70.4% of outstanding shares voted for, short of 80% requirement.","Supermajority elimination proposal also failed: 70.3% for, below 80% threshold.","Shareholder proposal for independent board chair rejected (33.7% for).","Ernst & Young ratified as auditor with 94.7% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98252,"accession_number":"0000059478-26-000043","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q1 revenue $19.8B (+56% YoY), raises FY guidance, FDA approves Foundayo","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 revenue $19.8B (up 56% YoY); reported EPS $8.26 (up 170%); non-GAAP EPS $8.55.","FY2026 revenue guidance raised to $82B-$85B; non-GAAP EPS guidance $35.50-$37.00.","U.S. FDA approved Foundayo (orforglipron) for obesity—first GLP-1 pill without food/water restrictions.","Acquired Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics.","Pipeline progress: positive Phase 3 for Foundayo in T2D, Jaypirca combo in CLL, and retatrutide in T2D."],"consensus_eps_estimate":null,"consensus_eps_actual":8.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":19799000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113608,"accession_number":"0000059478-26-000008","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q4 revenue up 43% to $19.3B; EPS $7.39 (+51%); FY2026 guidance $80-83B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $19.3B (+43% YoY); reported EPS $7.39 (+51%); non-GAAP EPS $7.54 (+42%), both incl. $0.52 acquired IPR&D.","FY2026 guidance: revenue $80-83B; non-GAAP EPS $33.50-$35.00.","FDA approved Kwikpen for tirzepatide; filed orforglipron for obesity in US, Japan, and EU.","Positive Phase 3 results for Taltz+Zepbound combo in psoriatic arthritis and retatrutide for knee osteoarthritis.","Agreement with U.S. government to expand access to obesity medicines for millions of Americans."],"consensus_eps_estimate":null,"consensus_eps_actual":22.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":65179000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130012,"accession_number":"0000059478-25-000271","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Eli Lilly elects Carolyn R. Bertozzi to board as independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carolyn R. Bertozzi, Ph.D elected to board effective Dec 8, 2025; will stand for election at May 2026 annual meeting.","Bertozzi is Anne T. and Robert M. Bass Professor of Chemistry at Stanford and HHMI Investigator.","She will serve on Science & Technology Committee and Ethics & Compliance Committee.","Board determined she is independent under NYSE standards and company guidelines.","She will participate in standard director compensation program as described in proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130011,"accession_number":"0000059478-25-000251","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q3 revenue up 54% to $17.6B; raises FY2025 guidance on Mounjaro/Zepbound demand","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 reported EPS $6.21 vs $1.07 YoY; non-GAAP EPS $7.02 vs $1.18.","Revenue $17.6B (up 54% YoY) driven by Mounjaro and Zepbound volume growth.","Raises FY2025 revenue guidance to $63.0-63.5B; reported EPS $21.80-22.50, non-GAAP EPS $23.00-23.70.","Pipeline: plans to submit orforglipron for obesity to global regulators by year-end after positive Phase 3 trials.","U.S. FDA approved Inluriyo (imlunestrant) for advanced/metastatic breast cancer; manufacturing expansions in VA, TX, Puerto Rico."],"consensus_eps_estimate":null,"consensus_eps_actual":15.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":45887000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146595,"accession_number":"0001193125-25-184093","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lilly raises $7.75B in multi-tranche debt offering; net proceeds ~$6.71B","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $7.75B across 7 tranches (floating-rate due 2028, fixed-rate due 2028-2065); closed Aug 20, 2025.","Net proceeds of approximately $6.71 billion after underwriting discounts and estimated expenses.","Key tranches: $1.25B 4.900% notes due 2035; $1B each of 4.000% due 2028, 4.550% due 2032, 5.550% due 2055, 5.650% due 2065.","Underwriting led by Citigroup, Goldman Sachs, J.P. Morgan, Mizuho, Morgan Stanley."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146594,"accession_number":"0000059478-25-000202","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q2 revenue $15.56B (+38% YoY), EPS $6.29 (+92%), raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $15.56B, up 38% YoY, driven by volume growth from Zepbound and Mounjaro.","Reported EPS $6.29, up 92%; non-GAAP EPS $6.31, up 61%, both inclusive of $0.14 IPR&D charges.","Full-year revenue guidance raised $1.5B to $60-62B; reported EPS guided $20.85-22.10; non-GAAP EPS $21.75-23.00.","Pipeline progress: positive results for orforglipron in obesity, Mounjaro SURPASS CVOT in T2D and heart disease, and Jaypirca vs Imbruvica in CLL/SLL.","Completed acquisitions of SiteOne Therapeutics and Verve Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":9.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":28286200000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164978,"accession_number":"0000059478-25-000138","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lilly annual meeting: directors reelected, classified board and supermajority amendments fail","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Four directors elected to three-year terms: Alvarez, Hedley, Johnson, Luciano, each with >726M votes for.","Advisory say-on-pay approved: 731.4M for, 28.0M against, 1.8M abstentions.","Ernst & Young ratified as auditor for 2025: 805.1M for, 40.8M against.","Classified board elimination failed: 658.8M for (69.5% of outstanding), below 80% threshold.","Supermajority voting elimination failed: 655.8M for (69.2% of outstanding), below 80% threshold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164977,"accession_number":"0000059478-25-000129","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q1 revenue up 45% to $12.73B; EPS beat; reaffirms guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.73B (+45% YoY) driven by Mounjaro and Zepbound volume growth.","Reported EPS $3.06 (+23%); non-GAAP EPS $3.34 (+29%), including $1.72 IPR&D charges.","Revenue guidance reaffirmed at $58.0-$61.0 billion for full-year 2025.","Pipeline: positive Phase 3 for oral GLP-1 orforglipron in T2D; approvals in oncology/immunology."],"consensus_eps_estimate":null,"consensus_eps_actual":3.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":12728500000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182691,"accession_number":"0001193125-25-025057","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eli Lilly issues $6.5B of notes across 6 tranches; net proceeds ~$6.46B","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issues $1B 4.550% notes due 2028, $1.25B 4.750% notes due 2030, $1B 4.900% notes due 2032.","Issues $1.25B 5.100% notes due 2035, $1.25B 5.500% notes due 2055, $750M 5.600% notes due 2065.","Net proceeds of approximately $6.46B after underwriting discounts; offering closed February 12, 2025.","Notes issued under existing indenture; redemption at company's option on specified terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182690,"accession_number":"0000059478-25-000037","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q4 2024 revenue up 45% to $13.53B, EPS $4.88; 2025 guidance of $58-61B revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $13.53B (+45% YoY); reported EPS $4.88 (+102%); non-GAAP EPS $5.32 (+114%).","Revenue growth driven by volume from Mounjaro and Zepbound; non-incretin revenue grew 20%.","2025 guidance: revenue $58.0-61.0B, reported EPS $22.05-23.55, non-GAAP EPS $22.50-24.00.","Pipeline: FDA approved Zepbound for OSA and Omvoh for Crohn's; Kisunla approved in China.","Board authorized $15B share repurchase program and 15% dividend increase."],"consensus_eps_estimate":null,"consensus_eps_actual":11.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":45042700000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182689,"accession_number":"0000059478-25-000005","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly updates 2024 revenue to ~$45B, Q4 ~$13.5B; guides 2025 revenue $58-61B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["2024 full-year revenue expected ~$45.0B, up 32% YoY and $4B above initial guidance midpoint.","Q4 2024 revenue ~$13.5B, up 45% YoY, but $400M below low end of Oct 30 guidance due to slower incretin growth and lower channel inventory.","Mounjaro Q4 revenue ~$3.5B, Zepbound ~$1.9B; non-incretin revenue grew 20% YoY.","2025 revenue guidance $58-61B, midpoint growth of 32% vs expected 2024; includes new product launches and manufacturing expansion.","Full Q4 2024 results and 2025 financial guidance to be reported on February 6, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":11.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":45042700000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199280,"accession_number":"0000059478-24-000258","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Eli Lilly elects P&G CEO Jon Moeller to board; Karen Walker resigns effective Dec 31","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jon Moeller, Chairman/CEO of Procter & Gamble, elected to Lilly board effective Dec 1, 2024.","Karen Walker resigns from board effective Dec 31, 2024; will collaborate on digital commercial activities in 2025.","Moeller will serve on Audit Committee and Directors and Corporate Governance Committee; stands for election at May 2026 annual meeting.","Walker's resignation not due to any disagreement with the company; she served since 2018 on Audit and Talent Committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199279,"accession_number":"0000059478-24-000242","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q3: Revenue $11.44B (+20% YoY); EPS $1.07/$1.18; FY revenue guidance raised to $45.4-$46.0B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $11.44B, up 20% YoY; excluding $1.42B prior-year olanzapine divestiture, revenue up 42%.","Reported EPS $1.07; non-GAAP EPS $1.18, both including $3.08 acquired IPR&D charges.","Mounjaro and Zepbound drove volume growth; non-incretin revenue up 17% ex-divestiture.","FY 2024 revenue guidance raised to $45.4-$46.0B; EPS guidance $12.05-$12.55 reported, $13.02-$13.52 non-GAAP.","Positive Phase 3 data for tirzepatide (94% diabetes risk reduction) and donanemab (reduced ARIA-E)."],"consensus_eps_estimate":null,"consensus_eps_actual":6.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":31509900000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215312,"accession_number":"0000059478-24-000213","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lilly appoints Lucas Montarce as EVP and CFO, effective Sept 9, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lucas Montarce, 47, promoted from president of Spain/Portugal/Greece hub to CFO, effective immediately.","He previously served as group VP, controller and CFO of Lilly Research Labs since 2021; joined Lilly in 2001.","Compensation includes $1M annual base salary and $1M target bonus; no family relationships or special arrangements.","CEO David Ricks cited Montarce's drive and integrity following an internal and external search across industries.","Montarce holds a BBA from Catholic University (Argentina) and an MBA from CEMA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215311,"accession_number":"0000059478-24-000196","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lilly director Marschall S. Runge to retire from board effective Aug. 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Runge served on board since 2013; retirement effective Aug. 31, 2024.","No replacement named; departure not due to any disagreement with company.","Runge also retiring as CEO of Michigan Medicine effective June 30, 2025; will remain on faculty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215310,"accession_number":"0001193125-24-200435","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eli Lilly issues $5B in notes across five tranches with maturities from 2027 to 2064","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $750M 4.150% notes due 2027, $1B 4.200% notes due 2029, $1.25B 4.600% notes due 2034, $1.25B 5.050% notes due 2054, $750M 5.200% notes due 2064.","Net proceeds approximately $4.96 billion after underwriting discounts and expenses.","Underwriting syndicate led by BNP Paribas, Citigroup, Goldman Sachs, J.P. Morgan, and Morgan Stanley.","Notes are unsecured and may be redeemed at the company's option prior to maturity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215309,"accession_number":"0000059478-24-000185","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q2 revenue up 36% to $11.3B, raises FY revenue guidance by $3B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $11.30B (+36% YoY); reported EPS $3.28 (+68%), non-GAAP EPS $3.92 (+86%).","FY revenue guidance raised $3B; reported EPS raised $2.05 to $15.10-15.60; non-GAAP EPS raised $2.60 to $16.10-16.60.","Growth driven by Mounjaro, Zepbound, and Verzenio; non-incretin revenue up 17% ex-Baqsimi rights sale.","Pipeline: FDA approval of Kisunla for Alzheimer's; tirzepatide submissions for sleep apnea; positive SUMMIT and QWINT trials.","Announced agreement to acquire Morphic Holding for oral integrin therapies; $5.3B manufacturing investment in Indiana."],"consensus_eps_estimate":null,"consensus_eps_actual":5.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":20070800000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215308,"accession_number":"0000059478-24-000164","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Eli Lilly CFO Anat Ashkenazi resigns; Gordon Brooks interim CFO from July 15","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anat Ashkenazi resigned as EVP and CFO to pursue opportunity outside pharma; stays through July for transition.","Gordon Brooks, group VP controller and corporate strategy, named interim CFO effective July 15, 2024.","Brooks has 29-year Lilly career including CFO of U.S. Bio-Medicines and chief procurement officer.","No arrangements or family relationships; selection not pursuant to any agreement with outsiders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234615,"accession_number":"0000059478-24-000146","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Eli Lilly CFO Anat Ashkenazi resigns; to leave in July 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anat Ashkenazi resigns as EVP and CFO to pursue a career opportunity outside the pharmaceutical industry.","She will continue in her role at full capacity and on the Executive Committee through July 2024.","An internal and external search for her successor is actively underway.","Ashkenazi served 23 years at Lilly, with 3 years as CFO overseeing growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234614,"accession_number":"0000059478-24-000127","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Eli Lilly annual meeting: directors elected, governance amendments fail","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four director nominees elected; Katherine Baicker received 768.7M for, 4.8M against.","Advisory say-on-pay approved with ~95% of votes cast (734M for, 38.6M against).","Ratification of Ernst & Young as auditor for 2024 passed with 819.7M for (95.7% of votes cast).","Proposal to eliminate classified board failed with 70.1% for, short of 80% requirement.","All five shareholder proposals (lobbying, DEI, patents, human rights) each received <25% support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234613,"accession_number":"0000059478-24-000116","cik":59478,"company_name":"ELI LILLY & Co","ticker":"LLY","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lilly Q1 revenue up 26% to $8.77B; raises full-year guidance by $2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 reported EPS $2.48 (up 66% YoY); non-GAAP EPS $2.58 (up 59% YoY), including $0.10 acquired IPR&D charges.","Revenue $8.77B, driven by Mounjaro, Zepbound, Verzenio, Jardiance; raised FY2024 revenue guidance by $2.0B.","Raises FY2024 reported EPS guidance to $13.05-$13.55 and non-GAAP EPS to $13.50-$14.00.","Pipeline progress: positive Phase 3 tirzepatide for OSA, mirikizumab submission for Crohn's, lebrikizumab resubmission.","Agreement to acquire injectable medicine manufacturing facility from Nexus Pharmaceuticals; broke ground on $2.5B German site."],"consensus_eps_estimate":null,"consensus_eps_actual":2.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":8768000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1019830581083.678,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}